Key Points Investors Should Note

• Approval of 2025 Annual Results: The Board will review and approve the audited annual financial results for the year ended 31 December 2025. This is a critical event, as the financial performance report is a primary driver of share price movement.
• Final Dividend Recommendation: The Board will also consider whether to recommend a final dividend. Any announcement regarding dividends – including the amount, timing, and eligibility – is highly price sensitive and directly affects investor returns and sentiment.
• Other Business Matters: The Board may also transact other relevant business. While unspecified, this opens the possibility for additional announcements, such as strategic initiatives, leadership changes, or corporate actions that could impact the company’s valuation.

Why This Announcement Matters to Shareholders

The review and approval of annual results are a key factor in determining the company’s financial health and future prospects. A strong set of results may drive the share price higher due to increased investor confidence, while disappointing numbers could trigger a decline. The dividend recommendation is particularly important for income-focused investors; any changes in dividend policy or payout could have immediate effects on the stock’s valuation.

Shareholders should also be aware of the possibility of other business being discussed, as unexpected announcements can lead to significant market reactions.

Board Composition

The current Board comprises a mix of executive, non-executive, employee representative, and independent non-executive directors. Leadership includes:

• Mr. Tang Yanggang (Vice Chairman, Executive Director)
• Mr. Zhu Baoguo (Chairman, Non-Executive Director)
• Mr. Lin Nanqi and Mr. Qiu Qingfeng (Non-Executive Directors)
• Ms. Ran Yongmei (Employee Representative Director)
• Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie, and Ms. Wang Zhiyao (Independent Non-Executive Directors)

The diversity and expertise of the Board may influence strategic decision-making and long-term value creation.

Potential Price Sensitive Information

• The results announcement and dividend recommendation are highly price sensitive. Investors should monitor for further updates or official disclosures following the Board meeting, as these will likely influence share price performance.
• Any additional business transacted at the meeting could also be price sensitive, depending on the nature of the decisions.

Disclaimer: This article is based on public disclosures and is intended for informational purposes only. It does not constitute investment advice. Investors should consult their financial advisors and conduct their own research before making any investment decisions. Livzon Pharmaceutical Group Inc. and its Board have not yet released specific financial results or dividend information. All forward-looking statements are subject to risks and uncertainties.

View LIVZON PHARMA Historical chart here